

IN THE CLAIMS

1. (Previously Amended) An isolated polypeptide, comprising at least 15 contiguous amino acid residues of an amino acid sequence of SEQ ID NO:48 selected from the group consisting of:

- (a) amino acid residues 24 to 230 of SEQ ID NO:48;
- (b) amino acid residues 27 to 230 of SEQ ID NO:48;
- (c) amino acid residues 27 to 126 of SEQ ID NO:48;
- (d) amino acid residues 131 to 230 of SEQ ID NO:48; and
- (e) amino acid residues 1 to 230 of SEQ ID NO:48.

2. (Previously Amended) An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:48 selected from the group consisting of:

- (a) amino acid residues 24 to 230 of SEQ ID NO:48;
- (b) amino acid residues 27 to 230 of SEQ ID NO:48;
- (c) amino acid residues 27 to 126 of SEQ ID NO:48;
- (d) amino acid residues 131 to 230 of SEQ ID NO:48; and
- (e) amino acid residues 1 to 230 of SEQ ID NO:48.

3. (Previously Amended) The isolated polypeptide of claim 2, wherein the polypeptide consists of an amino acid sequence of SEQ ID NO:48 selected from the group consisting of:

- (a) amino acid residues 24 to 230 of SEQ ID NO:48;
- (b) amino acid residues 27 to 230 of SEQ ID NO:48;
- (c) amino acid residues 27 to 126 of SEQ ID NO:48;
- (d) amino acid residues 131 to 230 of SEQ ID NO:48; and
- (e) amino acid residues 1 to 230 of SEQ ID NO:48.

Claims 4-16. (Previously Cancelled)

17. (Previously Amended) A fusion protein, comprising the polypeptide of claim 2.

18. (Original) The fusion protein of claim 17, wherein the fusion protein further comprises an immunoglobulin moiety.

Claims 19-44. (Previously Cancelled)

45. (Currently Amended) An isolated soluble cytokine receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:48 from amino acid 24 to 230, or 27 to 230, wherein the soluble cytokine receptor polypeptide ~~forms~~ further comprises a homodimeric, heterodimeric or multimeric receptor complex of cytokine receptors.

46. (Currently Amended) The isolated polypeptide according to claim 45, wherein the soluble cytokine receptor polypeptide ~~forms~~ further comprises a heterodimeric or multimeric receptor complex further comprising a soluble Class I or Class II cytokine receptor.

47. (Currently Amended) The isolated polypeptide according to claim 45, wherein the soluble cytokine receptor polypeptide ~~forms~~ further comprises a heterodimeric or multimeric receptor complex comprising a soluble Cytokine Receptor Family 2-4 (CRF2-4) receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

48. (Previously Amended) The isolated polypeptide according to claim 45, wherein the soluble cytokine receptor polypeptide further comprises an affinity tag, chemical moiety, toxin, label, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, cytotoxic molecule or an immunoglobulin Fc domain.

49. (Currently Amended) An isolated heterodimeric or multimeric soluble receptor complex comprising soluble cytokine receptor subunits, wherein at least one of the soluble cytokine receptor subunits comprises a soluble cytokine receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:48 from amino acid 24 to 230, or 27 to 230.

50. (Previously Amended) The isolated heterodimeric or multimeric soluble receptor complex according to claim 49, further comprising a soluble Class I or Class II cytokine receptor polypeptide.

51. (Currently Amended) The isolated heterodimeric or multimeric soluble receptor complex according to claim 49, further comprising a soluble Cytokine Receptor Family 2-4 (CRF2-4) receptor polypeptide (SEQ ID NO:35), a soluble IL-10 receptor polypeptide (SEQ ID NO:36), or soluble zcytor11 receptor polypeptide (SEQ ID NO:34).

Claims 52-67. (Previously Cancelled)

68. (Previously Added) The fusion protein of claim 17, wherein the fusion protein further comprises an affinity tag, chemical moiety, toxin, label, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, cytotoxic molecule or an immunoglobulin Fc domain.

69. (Currently Amended) The fusion protein of claim 17, wherein the fusion protein binds IL-10-Related T Cell-Derived Inducible Factor (IL-TIF) or antagonizes IL-TIF activity.

70. (Previously Added) The isolated heterodimeric or multimeric soluble receptor complex according to claim 49, wherein the soluble receptor complex further comprises

an affinity tag, chemical moiety, toxin, label, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, cytotoxic molecule or an immunoglobulin Fc domain.

71. (Currently Amended) An isolated soluble cytokine receptor polypeptide receptor complex comprising soluble cytokine receptor subunits, wherein at least one of soluble receptor subunits comprises a sequence of amino acid residues as shown in SEQ ID NO:48 from amino acid 24 to 230, or 27 to 230.

72. (Previously Added) The isolated soluble cytokine receptor polypeptide receptor complex of claim 71, wherein the receptor complex further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, cytotoxic molecule or an immunoglobulin Fc domain.

73. (Currently Amended) The isolated soluble cytokine receptor polypeptide receptor complex of claim 71, wherein the receptor complex binds IL-10-Related T Cell-Derived Inducible Factor (IL-TIF) or antagonizes IL-TIF activity.

74. (Currently Amended) The isolated soluble cytokine receptor polypeptide receptor complex of claim 49, wherein the receptor complex binds IL-10-Related T Cell-Derived Inducible Factor (IL-TIF) or antagonizes IL-TIF activity.